Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2013 1
2014 6
2015 1
2016 3
2017 1
2018 1
2019 6
2020 2
2021 5
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Bloemendal M, Bol KF, Boudewijns S, Gorris MAJ, de Wilt JHW, Croockewit SAJ, van Rossum MM, de Goede AL, Petry K, Koornstra RHT, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Bloemendal M, et al. Among authors: koornstra rht. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. Oncoimmunology. 2021. PMID: 36524210 Free PMC article. Clinical Trial.
[Pseudoprogression in immune therapy].
de Boer FJ, Stigt JA, Netters FJS, Koornstra RHT, Tije AJT, de Groot JWB. de Boer FJ, et al. Among authors: koornstra rht. Ned Tijdschr Geneeskd. 2019 Jul 5;163:D3247. Ned Tijdschr Geneeskd. 2019. PMID: 31283128 Dutch.
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, de Boer AJ, Bos KJH, Duiveman-de Boer T, Olde Nordkamp MAM, van Oorschot TGM, Popelier CJ, Pots JM, Scharenborg NM, van de Rakt MWMM, de Ruiter V, van Meeteren WS, van Rossum MM, Croockewit SJ, Koeneman BJ, Creemers JHA, Wortel IMN, Angerer C, Brüning M, Petry K, Dzionek A, van der Veldt AA, van Grünhagen DJ, Werner JEM, Bonenkamp JJ, Haanen JBAG, Boers-Sonderen MJ, Koornstra RHT, Boomsma MF, Aarntzen EHJ, Gotthardt M, Nagarajah J, de Witte TJM, Figdor CG, de Wilt JHW, Textor J, de Groot JWB, Gerritsen WR, de Vries IJM. Bol KF, et al. Among authors: koornstra rht. Nat Commun. 2024 Feb 23;15(1):1632. doi: 10.1038/s41467-024-45358-0. Nat Commun. 2024. PMID: 38395969 Free PMC article. Clinical Trial.
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
van Wilpe S, Simnica D, Slootbeek P, van Ee T, Pamidimarri Naga S, Gorris MAJ, van der Woude LL, Sultan S, Koornstra RHT, van Oort IM, Gerritsen WR, Kroeze LI, Simons M, van Leenders GJLH, Binder M, de Vries IJM, Mehra N. van Wilpe S, et al. Among authors: koornstra rht. Oncoimmunology. 2022 Jul 1;11(1):2094133. doi: 10.1080/2162402X.2022.2094133. eCollection 2022. Oncoimmunology. 2022. PMID: 35800157 Free PMC article.
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
van Wilpe S, Sultan S, Gorris MAJ, Somford DM, Kusters-Vandevelde HVN, Koornstra RHT, Gerritsen WR, Simons M, van der Heijden AG, de Vries IJM, Mehra N. van Wilpe S, et al. Among authors: koornstra rht. Cancer Immunol Immunother. 2023 Jan;72(1):137-149. doi: 10.1007/s00262-022-03234-0. Epub 2022 Jun 30. Cancer Immunol Immunother. 2023. PMID: 35771253 Free PMC article.
Dynamics of IGF-1R expression during endocrine breast cancer treatment.
Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Koornstra RH, Linn SC, Oyen WJ, van der Graaf WT, van Laarhoven HW. Heskamp S, et al. Among authors: koornstra rh. Mol Imaging Biol. 2014 Aug;16(4):529-37. doi: 10.1007/s11307-014-0723-6. Mol Imaging Biol. 2014. PMID: 24532107
30 results